MedicaidPrior AuthMedium impact
Empliciti (elotuzumab) (Revised)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has revised prior authorization requirements for Empliciti (elotuzumab) for multiple myeloma treatment. The policy establishes specific criteria for approval including disease progression requirements and mandatory combination therapies, with 6-month approval durations.
Action Required
Before September 1, 2025: Clinical staff must ensure prior authorization is obtained for all Empliciti (elotuzumab) prescriptions for Louisiana Medicaid patients with multiple myeloma. Verify patients meet progression criteria (1-3 prior therapies OR 2+ prior therapies including lenalidomide and proteasome inhibitor) and document required combination therapies. Update EMR templates to include necessary clinical documentation for approval. Claims will be denied without proper prior authorization.